Personality disorders (PD) are described as enduring patterns of markedly deviant and pervasive inner experiences and behaviors, with onset in adolescence, which lead to severe distress or impairment. Patients suffering from major depressive disorder (MDD) display higher rates of comorbidity with personality disorders, often complicating the treatment, and worsening the outcomes. Borderline personality disorder (BPD) is the most common of PD and is frequently associated with MDD, with which shares several features. The most part of research agrees on the fact that comorbid BPD in MDD patients quite doubles the poor response to treatments. Moreover, no treatment strategy stands out currently to emerge as more effective in these cases, thus urging the call for the need of new approaches. Herein, we revise the current literature on BPD, its neurobiology and comorbidity with MDD, as well as the more recent treatment strategies used. Then, based on its pharmacology, we propose a possible role of trazodone as a valuable tool to approach comorbid BPD-MDD.

Treating depression in patients with borderline personality disorder: clinical clues on the use of antidepressants / C. Tomasetti, G. Autullo, A. Ballerini, A. de Bartolomeis, B. Dell'Osso, A. Fiorentini, F. Tonioni, V. Villari, D. De Berardis. - In: ANNALS OF GENERAL PSYCHIATRY. - ISSN 1744-859X. - 23:1(2024 May 30), pp. 21.1-21.11. [10.1186/s12991-024-00507-z]

Treating depression in patients with borderline personality disorder: clinical clues on the use of antidepressants

A. Ballerini;B. Dell'Osso;A. Fiorentini;
2024

Abstract

Personality disorders (PD) are described as enduring patterns of markedly deviant and pervasive inner experiences and behaviors, with onset in adolescence, which lead to severe distress or impairment. Patients suffering from major depressive disorder (MDD) display higher rates of comorbidity with personality disorders, often complicating the treatment, and worsening the outcomes. Borderline personality disorder (BPD) is the most common of PD and is frequently associated with MDD, with which shares several features. The most part of research agrees on the fact that comorbid BPD in MDD patients quite doubles the poor response to treatments. Moreover, no treatment strategy stands out currently to emerge as more effective in these cases, thus urging the call for the need of new approaches. Herein, we revise the current literature on BPD, its neurobiology and comorbidity with MDD, as well as the more recent treatment strategies used. Then, based on its pharmacology, we propose a possible role of trazodone as a valuable tool to approach comorbid BPD-MDD.
Comorbidity; Emotion; Neurobiology; Psychiatric disorders; Serotonin antagonist/Reuptake inhibitors; Trazodone;
Settore MEDS-11/A - Psichiatria
30-mag-2024
Article (author)
File in questo prodotto:
File Dimensione Formato  
s12991-024-00507-z.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 885.81 kB
Formato Adobe PDF
885.81 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1121672
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact